Table 2

Summary of adverse events (all grades) and treatment discontinuation in 18 patients

No. (%)
Adverse events  
    Neuropathic pain 1 (6) 
    Peripheral neuropathy 2 (11) 
    Neutropenia 1 (6) 
    Headache 1 (6) 
    Hypertension 1 (6) 
    Infections 2 (11) 
    Thrombocytopenia 7 (39) 
    Platelet count 50 × 109/L to less than 150 × 109/L 5 (28) 
    Platelet count 25 × 109/L to less than 50 × 109/L 2 (11) 
Serious adverse events  
    Death due to progressive disease 1 (6) 
Adverse events leading to discontinuation  
    Progressive disease 6 (33) 
    Neuropathic pain 1 (6) 
    Peripheral neuropathy 1 (6) 
No. (%)
Adverse events  
    Neuropathic pain 1 (6) 
    Peripheral neuropathy 2 (11) 
    Neutropenia 1 (6) 
    Headache 1 (6) 
    Hypertension 1 (6) 
    Infections 2 (11) 
    Thrombocytopenia 7 (39) 
    Platelet count 50 × 109/L to less than 150 × 109/L 5 (28) 
    Platelet count 25 × 109/L to less than 50 × 109/L 2 (11) 
Serious adverse events  
    Death due to progressive disease 1 (6) 
Adverse events leading to discontinuation  
    Progressive disease 6 (33) 
    Neuropathic pain 1 (6) 
    Peripheral neuropathy 1 (6) 

or Create an Account

Close Modal
Close Modal